Charles River Laboratories International, Inc. (CRL)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for CRL is $309.33, 3.1% above the last close of $300.15 on Oct 16, 2026; targets range from $218.24 to $355.85. Rating consensus: Buy.
Snapshot
- P/E—
- P/E vs sector—
- P/E vs own—
- Target upside+3.1%
- ConsensusBuy
- Market cap$14.46B
- FCF yield+2.6%
- Insiders-$26.03M
- Earnings in19d
- News0.00
Why it moved
Charles River Laboratories International, Inc. (CRL) fell 2.0% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to CRL.
0 stories on the day (30-day average 0.4).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $300.15 · +71.6% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI56
- Support-8.0%
- Resistance—
- Off 52w high-3.4%
- Off ATH-34.5%
- 52w range$300.15
- Bollingerupper half
- MACD-0.14
- ATR+3.8%
- Volume0.7x
Analyst price targets
14 firms with a target in the last 12 months · last close $300.15 · as of Oct 16, 2026
Strong buy 4 · Buy 11 · Hold 2 · Sell 1 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue -2.7% year over year, free cash flow 14.8% of revenue, operating margin 11.9%.
| Q2 FY2026 | Jun 27, 2026 | $1B | -0.03 | $149M | 36.2% | 11.9% | -0.1% |
| Q1 FY2026 | Mar 28, 2026 | $996M | -0.30 | -$14.83M | 28.0% | 12.0% | -1.5% |
| Q4 FY2025 | Dec 27, 2025 | $994M | -5.62 | $58.57M | 31.0% | 12.1% | -27.8% |
| Q3 FY2025 | Sep 27, 2025 | $1B | 1.10 | $178M | 33.7% | 13.3% | 5.4% |
| Q2 FY2025 | Jun 28, 2025 | $1.03B | 1.06 | $169M | 34.6% | 9.7% | 5.1% |
| Q1 FY2025 | Mar 29, 2025 | $984M | 0.50 | $112M | 32.3% | 7.6% | 2.6% |
| Q4 FY2024 | Dec 31, 2024 | $1B | -4.22 | $83.75M | 28.4% | -16.7% | -21.5% |
| Q3 FY2024 | Sep 28, 2024 | $1.01B | 1.33 | $213M | 34.6% | 11.6% | 6.8% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $266.90 | -1.5% | -3.0% | +3.6% | 33.1 | $43.93B | |
| 2 |  | $436.95 | -1.6% | -1.6% | +4.4% | 109.0 | $42.9B | |
| 3 |  | $262.54 | -2.0% | -10.6% | -16.6% | 49.0 | $39.64B | |
| 4 |  | $1,622.29 | -1.0% | -1.0% | -7.3% | 36.5 | $32.51B | |
| 5 |  | $235.00 | -1.7% | -4.7% | -0.5% | 24.9 | $25.94B | |
| 6 |  | $317.95 | -2.2% | -6.1% | +5.8% | 26.3 | $25.79B | |
| 7 |  | $152.64 | -1.3% | -3.0% | -18.2% | 72.7 | $17.03B | |
| 8 | | $300.15 | -2.0% | -3.4% | +3.1% | — | $14.46B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.